Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**GW7845** is a synthetic small molecule acting as a potent and selective agonist of the nuclear receptor peroxisome proliferator-activated receptor gamma (**PPARγ**), which is involved in regulating metabolism, fatty acid β-oxidation, glucose utilization, cholesterol transport, and cellular differentiation[1][2][3][4][5][7][9]. GW7845 is also an L-tyrosine derivative, chemically described as (2S)-2-[(2-methoxycarbonylphenyl)amino]-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid[1][5]. Preclinical studies demonstrate that GW7845 can induce apoptosis, limit migration of cancer cells[3][8][10], and delay tumor formation (notably, in mouse mammary tumor models)[4][6]. GW7845 enhances expression of PPARγ-responsive genes, redirects macrophage cholesterol efflux to adipose tissue via SR-BI, and affects mitochondrial function, indicating a multifaceted role in cellular metabolism, signaling, and cancer biology[2][4][6][10]. GW7845 is used widely in research but not approved for therapeutic use in humans or animals[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GW7845.